Details of the Drug Combinations

General Information of This Drug (ID: DMVN3FU)

• Drug Name: CA-074Me (DMVN3FU)
• Synonyms: 147859-80-1; Cathepsin B Inhibitor IV; CA-074 methyl ester; CA-074 Me; Methyl N-({(2s,3s)-3-[(Propylamino)carbonyl]oxiran-2-Yl}carbonyl)-L-Isoleucyl-L-Prolinate; CA-074-Me; MFCD03452890; methyl N-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]carbonyl}-L-isoleucyl-L-prolinate; CA 074 methyl ester; CA 074Me; CA074Me; CA inhibitor 6; (S)-methyl 1-((2S,3S)-3-methyl-2-((2S,3S)-3-(propylcarbamoyl)oxirane-2-carboxamido)pentanoyl)pyrrolidine-2-carboxylate; PrNH-tES-Ile-Pro-OMe; epoxysuccinyl derivative 6; KBioGR_000234; KBioSS_000234; CHEMBL262103; SCHEMBL1974424; BDBM16503; KBio2_000234; KBio2_002802; KBio2_005370; KBio3_000467; KBio3_000468; DTXSID50881386; Bio2_000234; Bio2_000714; HMS1361L16; HMS3886D15; EX-A1196; ZINC4899858; s7420; CCG-268623; CS-6086; DB07223; CA-074 methyl ester (CA-074 Me); IDI1_033984; NCGC00163431-01; AC-32670; methyl (2S)-1-[(2S,3S)-3-methyl-2-[[(2S,3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylate; methyl (2S)-1-[(2S,3S)-3-methyl-2-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]formamido}pentanoyl]pyrrolidine-2-carboxylate; QC-10413; HY-100350; 859C801; Q27096448; (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester; CA074ME; N-(L-3-TRANS-PROPYLCARBAMOYLOXIRANE-2-CARBONYL)-L-ISOLEUCYL-L-PROLINE METHYL ESTER

Indication

Cardiac arrest; ICD 11: MC82; Status: Preclinical [1]; Cystic fibrosis; ICD 11: CA25; Status: Preclinical [1]; Pulmonary fibrosis; ICD 11: CB03.4; Status: Preclinical [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
CA-074Me + Ruxolitinib	DC41EUW	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[2]

References

• [1] Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855.
• [2] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.